Evidence map›Paper›PMID 17948074›Full record

Trial reportTexas Heart Institute journal2007

Oral ascorbic acid in combination with beta-blockers is more effective than beta-blockers alone in the prevention of atrial fibrillation after coronary artery bypass grafting.

Masoud Eslami, Roya Sattarzadeh Badkoubeh, Mehdi Mousavi, Hassan Radmehr, Mehrdad Salehi, Nafiseh Tavakoli, Mohamad Reza Avadi

2 registry-linked trialsOpen access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Texas Heart Institute journal, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 39 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 4 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03123107 phase1completednot on this mapstarted 2017, after this paper: background citation

Advancing the Cardiovascular Science of Vitamin C in Cardiac Surgery Patients

TypeinterventionalSponsorGeisinger ClinicRan2017 to 2019Enrolled6ConditionsCoronary Artery Bypass Graft SurgeryArmsAscorbic Acid
NCT06995586 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

The Synergistic Action of Vitamins and Dietary Supplements in Patients With Coronary Artery Bypass Grafting for Improving the Quality of Healthcare Delivery.

TypeinterventionalSponsorNicosia General HospitalRan2026 to 2028Enrolled108ConditionsCardio-pulmonary Bypass, Cardiovascular Diseases, Omega-3 Polyunsaturated Fatty Acids, Omega-3 SupplementationArmsVitamin C, Omega 3 PUFA (EPO/DHA), Lignin, Lactulose
3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 4 syntheses or guidelines pooled it, 97 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Oxidative stress and atrial fibrillation.Journal of molecular and cellular cardiology · 2024
    Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Postoperative Atrial Fibrillation Following Cardiac Surgery: From Pathogenesis to Potential Therapies.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2020
    Review
  15. Article
  16. Review
  17. New-onset atrial fibrillation: an update.Journal of anesthesia · 2018
    Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Masoud EslamiDepartment of Cardiovascular, Imam Khomeini Hospital, Tehran University of Medical Sciences, Tehran 14197-33141, Iran.
Roya Sattarzadeh Badkoubeh
Mehdi Mousavi
Hassan Radmehr
Mehrdad Salehi
Nafiseh Tavakoli
Mohamad Reza Avadi
Imam Khomeini Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Because adrenergic beta antagonists are not sufficient to prevent atrial fibrillation after coronary artery bypass grafting, this prospective, randomized trial was designed to evaluate the effects of ascorbic acid as an adjunct to beta-blockers. Fifty patients formed our ascorbic acid group, and another 50 patients formed our control group. All patients were older than 50 years, were scheduled to undergo coronary artery bypass grafting, and had been treated with beta-blockers for at least 1 week before surgery. The mean age of the population was 60.19+/-7.14 years; 67% of the patients were men. Patients in the ascorbic acid group received 2 g of ascorbic acid on the night before the surgery and 1 g twice daily for 5 days after surgery. Patients in the control group received no ascorbic acid. Patients in both groups continued to receive beta-blockers after surgery. Telemetry monitoring was performed in the intensive care unit, and Holter monitoring was performed for 4 days thereafter. The incidence of postoperative atrial fibrillation was 4% in the ascorbic acid group and 26% in the control group (odds ratio, 0.119; 95% confidence interval, 0.025-0.558, P = 0.002). We conclude that ascorbic acid is effective, in addition to being well-tolerated and relatively safe. Therefore, it can be prescribed as an adjunct to beta-blockers for the prophylaxis of post-bypass atrial fibrillation.

Indexed as

Adrenergic beta-AntagonistsAgedAntioxidantsAscorbic AcidAtrial FibrillationCoronary Artery BypassDrug Therapy, CombinationFemaleHumansLength of StayLogistic ModelsMaleMiddle AgedProspective StudiesAdrenergic beta-AntagonistsAntioxidantsAscorbic AcidAdrenergic beta-antagonistsanti-arrhythmia agents/administration & dosageascorbic acid/administration & dosage/therapeutic useatrial fibrillation/drug therapy/prevention & controlclinical trials coronary artery bypass/adverse effects

Identifiers

PMID17948074
PMCPMC1995047
OpenAlexW1534173372

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.